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a  b  s  t  r  a  c  t
Aim:  Evaluate  pretreatment  hemoglobin  values  as  a prognostic  factor  in patients  with  locally  advanced
head  and  neck  squamous  cell carcinoma  treated  with  concurrent  chemoradiotherapy.
Background:  Anemia  is  one  of the  most  prevalent  laboratory  abnormalities  in  oncological  disease.  It
leads  to a decrease  in  cellular  oxygen  supply,  altering  radiosensitivity  of tumor  cells  and  compromising
therapeutic  outcomes.
Materials and  Methods:  Retrospective  evaluation  of patients  with  HNSCC  treated  with  cCRT.  Primary  and
secondary  endpoint  was  to evaluate  the  correlation  of  Hb  levels  (≥12.5  g/dL  or <12.5  g/dL)  at  the  beginning
of  cCRT  with  overall  survival  (OS)  and  progression-free  survival  (PFS),  respectively.iomarkers
ead and neck neoplasms
hemoradiotherapy
Results: A  total  of  108  patients  were  identified.  With  a median  follow-up  of 16.10  months  median  OS  was
59.70 months  for Hb  ≥12.5 g/dL  vs.  14.13  months  for Hb  <12.5  g/dL (p = 0.004).  PFS  was  12.29  months  for
Hb  ≥12.5  g/dL  and  1.68  months  for  Hb  <12.5  g/dL  (p = 0.016).
Conclusions:  In this  analysis,  Hb  ≥12.5  g/dL  correlated  with  significantly  better  OS  and  PFS.  Further  studies
are  needed  to  validate  these  findings.
© 2020  Greater  Poland  Cancer  Centre.  Published  by Elsevier  B.V. All  rights  reserved.. Background
In 2018, head and neck tumors were estimated to account for
.7% of all new cancers and 13,740 of all number of cancer deaths
n the United States.1 Worldwide, head and neck tumors account
or more than 550,000 new cancer cases and 380,000 deaths from
ancer annually, with a predominance of squamous cell carcinoma
istology.2
Locoregionally advanced head and neck squamous cell car-
inoma (HNSCC) is associated with an increased risk of both
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aria, Av. Prof Egas Moniz, 1649-035 Lisbon, Portugal.
E-mail address: cecilia.alvim.moreira@gmail.com (C. Melo-Alvim).
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507-1367/© 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reslocal recurrence and distant metastases.3 Combined modality
approaches (surgery, radiation with or without chemotherapy) are
required to optimize the chances of long-term disease control and
data from randomized trials support integrated chemotherapy and
radiation as a standard treatment option for patients with advanced
tumors for whom an organ-preservation strategy is desirable.4
Despite these combined modality approaches, cure rates are poorer
for this subgroup compared with early-stage counterparts, ranging
from 10 to 65% depending on the primary site and disease extent
and, although treatment outcomes have improved with the addi-
tion of chemo to radiation therapy, locoregional recurrence remains
a significant concern, with 50–60% of patients experiencing local
disease recurrence within 2 years of diagnosis.3–5
Additionally, it should be emphasized that these treatment
options have substantial acute and late toxicities, with a significant
erved.
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Table  1
Patients baseline characteristics in the global population and stratified by pretreatment hemoglobin levels.
Global Hb < 12.5 g/dL Hb ≥ 12.5 g/dL p-Value
Patients, n 108 39 69
Age
Median, years 58.5 61.0 58.0 0.416
IQR,  years 50.0–64.0 53.0–64.0 49.5–64.0
Gender
Male, n (%) 101 (93.5) 35 (89.7) 66 (95.7) 0.250
Female, n (%) 7 (6.5) 4 (10.3) 3 (4.3)
Performance status – ECOG
0–1, n (%) 97 (89.8) 33 (84.6) 64 (92.8) 0.199
≥2,  n (%) 11 (10.2) 6 (15.4) 5 (7.2)
Alcoholic habits
Yes, n (%) 65 (60.2) 12 (30.8) 30 (43.5) 0.219
No,  n (%) 42 (38.9) 27 (69.2) 38 (55.1)
Missing data, n (%) 1 (0.9) – 1 (1.4)
Smoking habits
Yes, n (%) 99 (91.7) 35 (89.7) 64 (92.8) 0.720
No,  n (%) 9 (8.3) 4 (10.3) 5 (7.2)
Primary tumor site 0.006
Oral cavity, n (%) 39 (36.1) 14 (35.9) 25 (35.9) 0.638
Larynx, n (%) 20 (18.5) 3 (7.7) 17 (24.6)
Oral  cavity, n (%) 39 (36.1) 14 (35.9) 25 (35.9) 1.000
Pharynx, n (%) 32 (29.6) 11 (28.2) 21 (30.4)
Oral  cavity, n (%) 39 (36.1) 14 (35.9) 25 (35.9) 0.216
Pharyngolanryngeal, n (%) 17 (15.7) 11 (28.2) 6 (8.7)
Larynx, n (%) 20 (18.5) 3 (7.7) 17 (24.6) 0.888
Pharynx, n (%) 32 (29.6) 11 (28.2) 21 (30.4)
Larynx, n (%) 20 (18.5) 3 (7.7) 17 (24.6) 0.010
Pharyngolanryngeal, n (%) 17 (15.7) 11 (28.2) 6 (8.7)
Pharynx, n (%) 32 (29.6) 11 (28.2) 21 (30.4) 0.195
Pharyngolanryngeal, n (%) 17 (15.7) 11 (28.2) 6 (8.7)
Stage grouping 0.002
II,  n (%) 3 (2.8) 1 (2.6) 2 (2.9) 1.000
III,  n (%) 24 (22.2) 3 (7.7) 21 (30.4)
II,  n (%) 3 (2.8) 1 (2.6) 2 (2.9) 1.000
IVA,  n (%) 55 (50.9) 20 (51.3) 35 (50.7)
II,  n (%) 3 (2.8) 1 (2.6) 2 (2.9) 1.000
IVB,  n (%) 25 (23.1) 15 (38.5) 10 (14.5)
III,  n (%) 24 (22.2) 3 (7.7) 21 (30.4) 0.224
IVA,  n (%) 55 (50.9) 20 (51.3) 35 (50.7)
III,  n (%) 24 (22.2) 3 (7.7) 21 (30.4) 0.003
IVB,  n (%) 25 (23.1) 15 (38.5) 10 (14.5)
IVA,  n (%) 55 (50.9) 20 (51.3) 35 (50.7) 0.219
IVB,  n (%) 25 (23.1) 15 (38.5) 10 (14.5)
Follow-up























IQR, months 6.7–45.0 
QR: interquartile range; ECOG: Eastern Cooperative Oncology Group; Hb: hemoglo
mpact on patients’ quality of life and survival. Thus, efforts should
e employed to identify biomarkers of treatment outcomes in order
o adjust treatment for specific patient subgroups and improve
ancer control. Ideally, these biological markers should be easily
vailable, simple to use, and cost-effective, with blood cell count
eing one such example.6,7
Numerous studies have suggested that the presence of ane-
ia  is associated with worse local control and survival in various
ypes of cancer, such as head and neck.7–9 Although a direct asso-
iation between tumor hypoxia and anemia is unclear, anemia
s known to lead to decreased cell oxygenation and has been
hown to contribute to radiation and chemotherapy resistance
ia oxygen deprivation, a key element for the cytotoxic action
f these therapies.8,10,11 Final results from the French Head and
eck Oncology and Radiotherapy Group trial 94-01 showed that
tage and hemoglobin (Hb) levels before treatment were significant
rognostic factors for survival and locoregional control.12 A low
retreatment Hb level (inferior to 12.5 g/dL) was  found to be the
ost negative prognostic factor for overall survival (OS), specific
isease-free survival, and locoregional control during the study’s
wo-year follow-up, with a 92% probability of death in 37 (17%)–20.2 10.0–71.8
patients with Hb levels lower than 12.5 g/L (odds ratio 10.36; 95%
CI 3.07–34.97; p < 0.0001).12
2. Aim
The aim of the present retrospective analysis was to evaluate
pretreatment Hb values as a prognostic factor in patients with
locally advanced HNSCC treated with concurrent chemoradiother-
apy (cCRT). The proposed hypothesis is that higher pretreatment
Hb levels correlate with better survival.
3. Materials and methods
3.1. Study population
Patients with newly diagnosed locally advanced HNSCC treated
with cCRT at Hospital de Santa Maria – Centro Hospitalar Uni-
versitário Lisboa Norte between January 2008 and December
2018 were consecutively enrolled and retrospectively evaluated.
Patients underwent head and neck computerized tomography scan
for external beam radiotherapy (EBRT) planning, with 3-mm image




























Fig. 1. Kaplan–Meier curves of overall survival according to pretreatment he
hickness reconstruction. Target volumes and dose report were in
ccordance with specific International Commission on Radiation
nits (ICRU) for each EBRT technique applied.13–15 Patients treated
rom 2008 to 2014 were submitted to conformal EBRT (3D-CRT)
nd received 70 Gy in 35 fractions. Prescription dose was changed
o 69.96 Gy in 33 fractions after 2014 due to the introduction of
ntensity-modulated radiotherapy (IMRT) with an integrated boost
echnique. During EBRT, patients were scheduled to receive three
oses of intravenous cisplatin 100 mg/m2 on radiotherapy days 1,
2, and 43.
Twelve weeks after cCRT completion, patients were assessed for
reatment response by clinical examination and computed tomog-
aphy. Additional follow-up consisted of clinical examination every
 months in the first year and every 3–6 months in the second year.
fter 2 years, follow-up intervals were extended to once a year, with
adiographic assessment with computed tomography performed
very year or whenever clinical progression was suspected. Pro-
ression and treatment response were defined according to the
esponse Evaluation Criteria in Solid Tumors (RECIST).
The study primary endpoint was correlation of pretreatment Hb
evels – stratified by ≥12.5 g/dL or <12.5 g/dL – with OS. As sec-
ndary endpoint, correlation of pretreatment Hb levels with PFS
as investigated. The Hb cut off was established according to the
iterature.
Other clinical and laboratory baseline characteristics wereetrieved from patients’ clinical records whenever available: age,
erformance status according to the Eastern Cooperative Oncology
roup (ECOG PS), smoking and alcohol history, primary tumor loca-
ion, tumor grade, and staging according to the 7th edition of theobin levels. HR: hazard ratio; CI: confidence interval; Hb: hemoglobin
American Joint Committee on Cancer (AJCC). Additionally, date of
disease progression and time of death or last follow-up visit were
also collected.
3.2. Statistical analysis
Sample size was  not pre-planned, as this was a convenience
sample, only determined by pre-defined inclusion criteria.
Patients were categorized according to parameters included in
the analysis: gender (female vs. male), ECOG PS (0 or 1 vs. ≥2), pri-
mary tumor location (oral cavity vs. laryngopharyngeal, pharynx vs.
laryngopharyngeal, and larynx vs. laryngopharyngeal), tumor stage
(IV vs. others), smoking history (yes vs. no), and alcoholic habits
(yes vs. no). Median and interquartile range (IQR) were reported for
continuous variables and frequencies for categorical variables. To
compare categorical variables among groups, 2 and Fisher exact
tests were used whenever appropriate. The Mann–Whitney test
was used to compare medians.
Outcome measures consisted of OS and progression-free sur-
vival (PFS). OS was defined as time between treatment start and
death, irrespective of cause. PFS was  defined as time between
treatment start and time of progression (as established by RECIST
criteria) or death, whichever came first. Median OS and PFS were
obtained using the Kaplan–Meier method and log-rank test was
used to compare group outcomes. To assess the effect of analyzed
parameters in response duration and prognosis, univariate and
multivariate analyses were conducted using the Cox regression
model. All statistical tests were two-tailed and statistical signifi-
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Table  2
Prognostic role of baseline characteristics and pretreatment hemoglobin levels: univariate and multivariate analysis for overall survival.
OS Univariate Multivariate
HR 95% CI p-Value HR 95% CI p-Value
Hemoglobin
<12.5 g/dL vs. ≥12.5 g/dL 2.26 1.29–3.99 0.005 1.97 1.10–3.53 0.004
Gender
Female vs. male 0.95 0.30–3.04 0.927 – – –
Smoking habits
Yes vs. no 1.35 0.49–3.75 0.567 0.540a
Alcoholic habits
Yes vs. no 0.88 0.52–1.52 0.654 – – –
ECOG
0–1  vs. ≥2 0.77 0.33–1.80 0.542 0.926a
Primary tumor site 0.150 0.066a
Larynx vs. pharyngolaryngeal 0.98 0.35–2.77 0.972
Pharynx vs. pharyngolaryngeal 1.04 0.40–2.67 0.937
Oral cavity vs. pharyngolaryngeal 1.94 0.79–4.77 0.150
Stage grouping
IV vs. others 2.02 1.03–3.97 0.040 0.128a
OS: overall survival; IQR: interquartile range; HR: hazard ratio; ECOG: Eastern Cooperative Oncology Group; Hb: hemoglobin.
a Included in multivariate analysis due to its prognostic factor.
Table 3
Prognostic role of baseline characteristics and pretreatment hemoglobin levels: univariate and multivariate analysis for progression-free survival.
PFS Univariate Multivariate
HR 95% CI p-Value HR 95% CI p-Value
Hemoglobin
<12.5 g/dL vs. ≥12.5 g/dL 2.22 1.38–3.59 0.001 1.89 1.12–3.17 0.016
Gender
Female vs. male 0.69 0.25–1.89 0.469 – – –
Smoking habits
Yes vs. no 0.57 0.23–1.41 0.221 0.224a
Alcoholic habits
Yes vs. no 0.94 0.59–1.50 0.802 – – –
ECOG
0–1  vs. ≥2 0.71 0.34–1.48 0.357 0.515a
Primary tumor site 0.001 0.013
Larynx vs. pharyngolaryngeal 0.41 0.17–1.00 0.050 0.65 0.25–1.69 0.374
Pharynx vs. pharyngolaryngeal 0.61 0.30–1.26 0.182 0.91 0.42–1.99 0.812
Oral  cavity vs. pharyngolaryngeal 1.58 0.81–3.06 0.180 1.93 0.99–3.87 0.062
Stage  grouping


















FS: progression free survival; IQR: interquartile range; HR: hazard ratio; ECOG: Ea
a Included in multivariate analysis due to its prognostic factor.
ance was assumed when the p-value was inferior to 0.05. IBM’s
PSS statistics v.24 was used for statistical analysis.
. Results
A total of 108 patients were treated with cCRT during the
early 10-year period. All patients had sufficient follow-up data
12 weeks) and were thus eligible for study inclusion.
.1. Baseline characteristics
Study cohort had a median of 58.5 years (IQR 50.0–64.0;
in–max 18.0–77.0), with 93.5% of males and 89.8% of ≤1 ECOG PS
atients. Most patients had been previously exposed to risk factors
ncluding alcohol and tobacco smoke (60.2% and 91.7%, respec-
ively) and the most prevalent primary tumor site was the oral
avity (36.1%), followed by the pharynx (29.6%). Eighty patients
74.0%) had stage IV disease and only 2.8% of patients had early-
tage disease and were eligible for cCRT instead of a unimodality
herapeutic approach.
Pretreatment Hb levels ≥12.5 g/dL were observed in 63.9% of
atients. None of the patients included in this study had history
f blood transfusion prior to the start of cCRT. Groups stratifiedCooperative Oncology Group; Hb: hemoglobin.
according to pretreatment Hb levels had well-balanced baseline
characteristics, apart from primary tumor location and staging. It
should be highlighted that ECOG PS was  worse in 15% of patients
with pretreatment Hb <12.5 g/dL in contrast with 7% of patients
with pretreatment Hb ≥12.5 g/dL and almost 40% of patients with
pretreatment Hb <12.5 g/dL are stage IVb versus only 15% in the
group with pretreatment Hb ≥12.5 g/dL. Characteristics of both
groups are detailed in Table 1.
The overall median follow-up was 16.1 months (IQR 6.7–45.0).
A total of 54 patients (50.0%) had died by the time of last follow-up,
with a median time to death of 33.0 months (95% CI 10.0–56.0),
33 of which in the ≥12.5 g/dL pretreatment Hb level group and 21
in the <12.5 g/dL pretreatment Hb level group. Fifty-four patients
remained on regular follow-up after cCRT completion, with regular
radiographic assessment for disease progression.
4.2. Survival in cCRT-treated patients, stratified by pretreatment
Hb levelsMedian OS by Kaplan–Meier analysis (Fig. 1) was  significantly
longer for patients with pretreatment Hb ≥12.5 g/dL compared
with those with pretreatment Hb <12.5 g/dL (59.70 months, 95%
CI 3.91–24.34 vs. 14.13 months, 95% CI 31.02–88.37). Patients with























Fig. 2. Kaplan–Meier curves of progression-free survival according to pretreatm
retreatment Hb levels <12.5 g/dL were 2.26 times more likely to
ie compared with patients with pretreatment Hb levels ≥12.5 g/dL
p = 0.004). OS analysis is shown in Table 2.
In univariate analysis, only stratified pretreatment Hb levels and
taging group were associated with better OS (Table 2). After adjust-
ng for confounding and clinically significant factors, multivariate
nalysis revealed that pretreatment Hb levels ≥12.5 g/dL remained
redictive of better survival (HR 1.97, 95% CI 1.10–3.53, p = 0.004)
Table 2).
.3. Duration of response in cCRT-treated patients, stratified by
retreatment Hb levels
Median PFS was significantly longer in the ≥12.5 g/dL pretreat-
ent Hb group (12.29 months, 95% CI 0.00–30.36) than in the
12.5 g/dL pretreatment Hb group (1.68 months, 95% CI 1.54–1.81;
able 3). Patients with lower pretreatment Hb levels were 2.22
imes more likely to experience disease progression compared
ith those with higher pretreatment Hb levels (p = 0.016). PFS
aplan–Meier curves are shown in Fig. 2. In multivariate analysis,
fter adjusting for confounding and clinically significant param-
ters, <12.5 g/dL pretreatment Hb levels remained predictive of
orse PFS (HR 1.89, 95% CI 1.12–3.17, p = 0.016) (Table 3).. Conclusion
Low Hb is an easily accessible and cheap marker of systemic
nflammation capable of guiding clinical decisions regarding sur-emoglobin levels. HR: hazard ratio; CI: confidence interval; Hb: hemoglobin
vival and recurrence among locally advanced HNSCC patients
undergoing cCRT. Evidence suggests that in some solid tumors as
head and neck, low Hb levels correlate with detrimental tumor
oxygenation and hence diminished control rate and survival out-
comes, even after adjusting for others prognostic parameters.16–21
Research regarding adaptation of tumor cells to oxygen variations
is key and was granted the Nobel Prize in Physiology or Medicine
in 2019.
The mechanism underlying poor prognosis is not properly
established and may  depend on the therapeutic approach. For
instance, in radiotherapy-treated patients, it is hypothesized that
anemia may  predispose to tumor hypoxia and, hence, to radi-
ation resistance. Pretreatment hemoglobin levels reflect blood’s
oxygen-binding capacity, which is crucial both for tumor oxygen
supply and for tumor cell response to cytotoxic therapy, partic-
ularly radiotherapy.6,19–22 Radiation ionizes water molecules and
forms reactive oxygen species which react with deoxyribonucleic
acid (DNA) and form DNA radicals. If available, in satisfactory
amounts, oxygen reacts with DNA radicals and repairs radiation-
induced DNA damage. Therefore, the tumor cell-killing ability of
ionizing radiation is enhanced by oxygen up to 2.5–3 times, named
the oxygen enhancement ratio.16,20–22
When analyzing the impact of low Hb levels, the Hb cut-off
value that may be useful for prognostic stratification should also
be addressed.16 Conflicting results may  be observed with differ-
ent cut-offs or anemia definitions, potentially affecting reported
outcomes. The impact of blood transfusions and erythropoietin
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tin is indicated for supportive care during treatment, but its
mpact on disease control and survival is not known. DAHANCA 10
nterim results were alarming because patients had worse event-
ree survival (HR 1.36 [1.09–1.69]), disease-specific death (HR
.43 [1.08–1.90]), and OS (HR 1.30 [1.02–1.64]) when darbepoetin
lfa was administered to increase Hb values (>14.0 g/dL) with-
ut increased cardiovascular events.22 Phase III studies addressing
his question and the impact of blood transfusions are therefore
equired.19 Recent studies are preferentially focused on the hypoxic
tatus of HNSCC tumors rather than on Hb levels, with the purpose
f investigating the value of functional imaging hypoxic markers,
ene signatures, and new treatment strategies as specific hypoxic
adiosensitizers (e.g. nimorazole).20–25
In line with previous studies, the present data shows that pre-
CRT Hb values lower than 12.5 g/dL adversely affect OS (p = 0.005)
nd PFS (p = 0.001) outcomes in HNSCC patients. In multivariate
nalysis, pretreatment Hb levels remained a significant indepen-
ent predictor of both OS (p = 0.004) and PFS (p = 0.016). Smoking
abits were considered in this study for their prognostic role and for
heir impact on formation of carboxyhemoglobin, with subsequent
ypoxia increase and radiation response decrease.26
Also, importantly, in this study patients with a pretreatment
b value inferior to 12.5 g/dL were 2.26 more likely to die. Given
his result, this parameter should be quantified and considered
s a stratification factor in future randomized clinical trials. Addi-
ionally, efforts should be made to use these same alterations for
mproving the quality of life measurements, although at present
ime data regarding the impact of Hb correction in these patients’
utcomes is still lacking.20,26,27
Although this study suggests a potential role for pretreatment
b levels as both a prognostic and predictive marker in locally
dvanced HNSCC treated with cCRT, it has some limitations. The
rimary is its small sample size and retrospective nature, with
ifferent sub-locations of disease that do not have the same bio-
ogical behavior and prognostic. Moreover, each subgroup has a
imited number of patients, so when analyzing the results, the
mpact of this biases associated with others, like the potentially
issing data regarding clinical variables like toxicities or treat-
ent interruptions, could increase, and the statistical power of this
nalysis can decrease. Second, this investigation was constrained
o pretreatment Hb levels, not considering the potential impact of
nemia diagnosed during treatment or of further lowered Hb levels
hroughout cCRT. Such variations may  alter the true rate of anemic
atients in this sample, with a potential impact in retrieved results.
hird, it is also important to address the lack of information about
uman papillomavirus (HPV) status. In our institution this data is
nly available since 2018, with only two p16-posite oropharyn-
eal squamous-cell carcinoma in concordance with the fact that
he major risk factor for HNSCC in Portugal is smoking habits.
espite this, we recognize the potential bias of HPV infection, as
ecent studies have shown that hemoglobin concentration is also
n independent prognostic factor for patients with p16-positive
ropharyngeal squamous-cell carcinoma.28
In the present study, pretreatment Hb levels were an indepen-
ent prognostic and predictive factor for survival outcomes, with
igher pretreatment levels associated with duration and survival
enefit in patients with locally advanced HNSCC treated with cCRT.
hese results are not novel, showing consistency with previously
eported studies. Despite this, efforts to determine the mechanism
y which anemia exerts its biologically detrimental effects and to
scertain the impact of its early correction in patient outcomes
hould be pursued and extended to other potential prognostic fac-
ors in order to better characterize individual prognosis and allow
or a more tailored therapeutic approach, avoiding unnecessary
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